Clinical Trial

Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD

Study acronym: DECODE-CKD
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 10, 2025 (before its estimated February 18, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to investigate the effects of dapagliflozin on echocardiographic measures of cardiac structure and function in patients with chronic kidney disease.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-04-28; most recent amendment 2025-02-06.
Status change: Not Yet Recruiting → Recruiting 2022-12-21
Trial Details
NCT Number NCT05359263
Lead Sponsor Tor Biering-Sørensen
Conditions Chronic Kidney Diseases
Enrollment 222 participants
Start Date 2022-06-08
Primary Completion 2025-02-18 (estimated)
Study Completion 2025-02-18 (estimated)
Updated on ClinicalTrials.gov 2025-02-10